Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Mostrar otras versiones (1)

BACKGROUND: This exploratory analysis evaluated second-line (2L) therapy for metastatic pancreatic cancer in a large phase 3 trial (MPACT). METHODS: Patients who received first-line (1L) nab-paclitaxel+gemcitabine (nab-P+Gem) or Gem were assessed for survival based on 2L treatment received. Multivar...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiorean, E Gabriela, Von Hoff, Daniel D, Tabernero, Josep, El-Maraghi, Robert, Ma, Wen Wee, Reni, Michele, Harris, Marion, Whorf, Robert, Liu, Helen, Li, Jack Shiansong, Manax, Victoria, Romano, Alfredo, Lu, Brian, Goldstein, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947701/
https://www.ncbi.nlm.nih.gov/pubmed/27351217
http://dx.doi.org/10.1038/bjc.2016.185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947701/
https://www.ncbi.nlm.nih.gov/pubmed/27351217
http://dx.doi.org/10.1038/bjc.2016.185

Ejemplares similares